Sanjay Basu1, Eran Bendavid2, Neeraj Sood2. 1. From the Department of Medicine Prevention Research Center, Center for Primary Care and Outcomes Research, (S.B., E.B.), Department of Medicine Stanford Institute for Economic Policy Research, Prevention Research Center (S.B.), and Division of General Medical Disciplines (E.B.), Stanford University, Stanford, CA; Department of Economics National Bureau of Economic Research, Center for International Development, Stanford Institute for Economic Policy Research, Stanford, CA (S.B.); Department of Public Health and Policy, London School of Hygiene and Tropical Medicine, London, United Kingdom (S.B.); Department of Pharmaceutical Economics and Policy and Schaeffer Center for Health Policy and Economics, University of Southern California, Los Angeles (N.S.); and National Bureau of Economic Research, Cambridge, MA (N.S.). basus@stanford.edu. 2. From the Department of Medicine Prevention Research Center, Center for Primary Care and Outcomes Research, (S.B., E.B.), Department of Medicine Stanford Institute for Economic Policy Research, Prevention Research Center (S.B.), and Division of General Medical Disciplines (E.B.), Stanford University, Stanford, CA; Department of Economics National Bureau of Economic Research, Center for International Development, Stanford Institute for Economic Policy Research, Stanford, CA (S.B.); Department of Public Health and Policy, London School of Hygiene and Tropical Medicine, London, United Kingdom (S.B.); Department of Pharmaceutical Economics and Policy and Schaeffer Center for Health Policy and Economics, University of Southern California, Los Angeles (N.S.); and National Bureau of Economic Research, Cambridge, MA (N.S.).
Abstract
BACKGROUND: Whether to cover cardiovascular disease costs is an increasingly pressing question for low- and middle-income countries. We sought to identify the impact of expanding national insurance to cover primary prevention, secondary prevention, and tertiary treatment for cardiovascular disease in India. METHODS AND RESULTS: We incorporated data from coverage experiments into a validated microsimulation model of myocardial infarction and stroke in India to evaluate the cost-effectiveness of alternate coverage strategies. Coverage of primary prevention alone saved 3.6 million disability-adjusted life-years (DALY) per annum at an incremental cost-effectiveness ratio of $469 per DALY averted when compared with the status quo of no coverage. Coverage of primary and secondary preventions was dominated by a strategy of covering primary prevention and tertiary treatment, which prevented 6.6 million DALYs at an incremental cost-effectiveness ratio of $2241 per DALY averted, when compared with that of primary prevention alone. The combination of all 3 categories yielded the greatest impact at an incremental cost per DALY averted of $5588 when compared with coverage of primary prevention plus tertiary treatment. When compared with the status quo of no coverage, coverage of all 3 categories of prevention/treatment yielded an incremental cost-effectiveness ratio of $1331 per DALY averted. In sensitivity analyses, coverage of primary preventive treatments remained cost-effective even if adherence and access to therapy were low, but tertiary coverage would require avoiding unnecessary procedures to remain cost-effective. CONCLUSIONS: Coverage of all 3 major types of cardiovascular treatment would be expected to have high impact and reasonable cost-effectiveness in India across a broad spectrum of access and adherence levels.
BACKGROUND: Whether to cover cardiovascular disease costs is an increasingly pressing question for low- and middle-income countries. We sought to identify the impact of expanding national insurance to cover primary prevention, secondary prevention, and tertiary treatment for cardiovascular disease in India. METHODS AND RESULTS: We incorporated data from coverage experiments into a validated microsimulation model of myocardial infarction and stroke in India to evaluate the cost-effectiveness of alternate coverage strategies. Coverage of primary prevention alone saved 3.6 million disability-adjusted life-years (DALY) per annum at an incremental cost-effectiveness ratio of $469 per DALY averted when compared with the status quo of no coverage. Coverage of primary and secondary preventions was dominated by a strategy of covering primary prevention and tertiary treatment, which prevented 6.6 million DALYs at an incremental cost-effectiveness ratio of $2241 per DALY averted, when compared with that of primary prevention alone. The combination of all 3 categories yielded the greatest impact at an incremental cost per DALY averted of $5588 when compared with coverage of primary prevention plus tertiary treatment. When compared with the status quo of no coverage, coverage of all 3 categories of prevention/treatment yielded an incremental cost-effectiveness ratio of $1331 per DALY averted. In sensitivity analyses, coverage of primary preventive treatments remained cost-effective even if adherence and access to therapy were low, but tertiary coverage would require avoiding unnecessary procedures to remain cost-effective. CONCLUSIONS: Coverage of all 3 major types of cardiovascular treatment would be expected to have high impact and reasonable cost-effectiveness in India across a broad spectrum of access and adherence levels.
Authors: Branko Kopjar; Anne E B Sales; Sandra L Piñeros; Haili Sun; Yu-Fang Li; Ashley N Hedeen Journal: Am J Cardiol Date: 2003-11-01 Impact factor: 2.778
Authors: Harlan M Krumholz; Yun Wang; Jersey Chen; Elizabeth E Drye; John A Spertus; Joseph S Ross; Jeptha P Curtis; Brahmajee K Nallamothu; Judith H Lichtman; Edward P Havranek; Frederick A Masoudi; Martha J Radford; Lein F Han; Michael T Rapp; Barry M Straube; Sharon-Lise T Normand Journal: JAMA Date: 2009-08-19 Impact factor: 56.272
Authors: Goodarz Danaei; Mariel M Finucane; Yuan Lu; Gitanjali M Singh; Melanie J Cowan; Christopher J Paciorek; John K Lin; Farshad Farzadfar; Young-Ho Khang; Gretchen A Stevens; Mayuree Rao; Mohammed K Ali; Leanne M Riley; Carolyn A Robinson; Majid Ezzati Journal: Lancet Date: 2011-06-24 Impact factor: 79.321
Authors: Joshua A Salomon; Theo Vos; Daniel R Hogan; Michael Gagnon; Mohsen Naghavi; Ali Mokdad; Nazma Begum; Razibuzzaman Shah; Muhammad Karyana; Soewarta Kosen; Mario Reyna Farje; Gilberto Moncada; Arup Dutta; Sunil Sazawal; Andrew Dyer; Jason Seiler; Victor Aboyans; Lesley Baker; Amanda Baxter; Emelia J Benjamin; Kavi Bhalla; Aref Bin Abdulhak; Fiona Blyth; Rupert Bourne; Tasanee Braithwaite; Peter Brooks; Traolach S Brugha; Claire Bryan-Hancock; Rachelle Buchbinder; Peter Burney; Bianca Calabria; Honglei Chen; Sumeet S Chugh; Rebecca Cooley; Michael H Criqui; Marita Cross; Kaustubh C Dabhadkar; Nabila Dahodwala; Adrian Davis; Louisa Degenhardt; Cesar Díaz-Torné; E Ray Dorsey; Tim Driscoll; Karen Edmond; Alexis Elbaz; Majid Ezzati; Valery Feigin; Cleusa P Ferri; Abraham D Flaxman; Louise Flood; Marlene Fransen; Kana Fuse; Belinda J Gabbe; Richard F Gillum; Juanita Haagsma; James E Harrison; Rasmus Havmoeller; Roderick J Hay; Abdullah Hel-Baqui; Hans W Hoek; Howard Hoffman; Emily Hogeland; Damian Hoy; Deborah Jarvis; Ganesan Karthikeyan; Lisa Marie Knowlton; Tim Lathlean; Janet L Leasher; Stephen S Lim; Steven E Lipshultz; Alan D Lopez; Rafael Lozano; Ronan Lyons; Reza Malekzadeh; Wagner Marcenes; Lyn March; David J Margolis; Neil McGill; John McGrath; George A Mensah; Ana-Claire Meyer; Catherine Michaud; Andrew Moran; Rintaro Mori; Michele E Murdoch; Luigi Naldi; Charles R Newton; Rosana Norman; Saad B Omer; Richard Osborne; Neil Pearce; Fernando Perez-Ruiz; Norberto Perico; Konrad Pesudovs; David Phillips; Farshad Pourmalek; Martin Prince; Jürgen T Rehm; Guiseppe Remuzzi; Kathryn Richardson; Robin Room; Sukanta Saha; Uchechukwu Sampson; Lidia Sanchez-Riera; Maria Segui-Gomez; Saeid Shahraz; Kenji Shibuya; David Singh; Karen Sliwa; Emma Smith; Isabelle Soerjomataram; Timothy Steiner; Wilma A Stolk; Lars Jacob Stovner; Christopher Sudfeld; Hugh R Taylor; Imad M Tleyjeh; Marieke J van der Werf; Wendy L Watson; David J Weatherall; Robert Weintraub; Marc G Weisskopf; Harvey Whiteford; James D Wilkinson; Anthony D Woolf; Zhi-Jie Zheng; Christopher J L Murray; Jost B Jonas Journal: Lancet Date: 2012-12-15 Impact factor: 79.321
Authors: Joshua A Salomon; Natalie Carvalho; Cristina Gutiérrez-Delgado; Ricardo Orozco; Anna Mancuso; Daniel R Hogan; Diana Lee; Yuki Murakami; Lakshmi Sridharan; María Elena Medina-Mora; Eduardo González-Pier Journal: BMJ Date: 2012-03-02
Authors: B Mihaylova; J Emberson; L Blackwell; A Keech; J Simes; E H Barnes; M Voysey; A Gray; R Collins; C Baigent Journal: Lancet Date: 2012-05-17 Impact factor: 79.321
Authors: Kavita Singh; Mohammed K Ali; Raji Devarajan; Roopa Shivashankar; Dimple Kondal; Vamadevan S Ajay; V Usha Menon; Premlata K Varthakavi; Vijay Viswanathan; Mala Dharmalingam; Ganapati Bantwal; Rakesh Kumar Sahay; Muhammad Qamar Masood; Rajesh Khadgawat; Ankush Desai; Dorairaj Prabhakaran; K M Venkat Narayan; Victoria L Phillips; Nikhil Tandon Journal: Glob Health Res Policy Date: 2019-03-18